Cargando…
Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma
PURPOSE: Primary radiochemotherapy (RCT) constitutes the standard of care for early- and advanced-stage anal carcinoma. This retrospective study investigates the impact of dose escalation on colostomy-free survival (CFS), overall survival (OS), locoregional control (LRC), progression-free survival (...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361861/ https://www.ncbi.nlm.nih.gov/pubmed/36862155 http://dx.doi.org/10.1007/s00066-023-02056-y |
_version_ | 1785076301720190976 |
---|---|
author | Untiedt, Sebastian Rolf, Daniel Scobioala, Sergiu Wolters, Heidi Elsayad, Khaled Oertel, Michael Kittel, Christopher Pascher, Andreas Rijcken, Emile Ullerich, Hansjörg Glasbrenner, Bernhard Eich, Hans Theodor |
author_facet | Untiedt, Sebastian Rolf, Daniel Scobioala, Sergiu Wolters, Heidi Elsayad, Khaled Oertel, Michael Kittel, Christopher Pascher, Andreas Rijcken, Emile Ullerich, Hansjörg Glasbrenner, Bernhard Eich, Hans Theodor |
author_sort | Untiedt, Sebastian |
collection | PubMed |
description | PURPOSE: Primary radiochemotherapy (RCT) constitutes the standard of care for early- and advanced-stage anal carcinoma. This retrospective study investigates the impact of dose escalation on colostomy-free survival (CFS), overall survival (OS), locoregional control (LRC), progression-free survival (PFS), and acute and late toxicities in patients with squamous cell anal cancer. METHODS: Considered were the outcomes of 87 patients with anal cancer treated with radiation/RCT between May 2004 and January 2020 at our institution. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0). RESULTS: The 87 patients received treatment with a median boost of 63 Gy to the primary tumor. With a median follow-up of 32 months, the 3‑year CFS, OS, LRC, and PFS were 79.5%, 71.4%, 83.9%, and 78.5%, respectively. Tumor relapse occurred in 13 patients (14.9%). Dose escalation to > 63 Gy (maximum 66.6 Gy) to the primary tumor in 38/87 patients revealed a nonsignificant trend for improved 3‑year CFS (82.4% vs. 97%, P = 0.092), a significantly improved CFS for T2/T3 tumors (72.6% vs. 100%, P = 0.008), and a significantly improved 3‑year PFS for T1/T2 tumors (76.7% vs. 100%, P = 0.035). While acute toxicities did not differ, dose escalation > 63 Gy led to a higher rate of chronic skin toxicities (43.8% vs. 69%, P = 0.042). Treatment with intensity-modulated radiotherapy (IMRT) showed a significant improvement in 3‑year OS (75.4% vs. 53.8%, P = 0.048). In multivariate analysis, significant improvements for T1/T2 tumors (CFS, OS, LRC, PFS), G1/2 tumors (PFS), and IMRT (OS) were shown. The nonsignificant trend for CFS improvement with dose escalation > 63 Gy was also apparent in multivariate analysis (P = 0.067). CONCLUSION: Dose escalation > 63 Gy (maximum 66.6 Gy) may improve CFS and PFS for certain subgroups, with a concomitant increase in chronic skin toxicities. Modern IMRT seems to be associated with an improvement in OS. |
format | Online Article Text |
id | pubmed-10361861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103618612023-07-23 Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma Untiedt, Sebastian Rolf, Daniel Scobioala, Sergiu Wolters, Heidi Elsayad, Khaled Oertel, Michael Kittel, Christopher Pascher, Andreas Rijcken, Emile Ullerich, Hansjörg Glasbrenner, Bernhard Eich, Hans Theodor Strahlenther Onkol Original Article PURPOSE: Primary radiochemotherapy (RCT) constitutes the standard of care for early- and advanced-stage anal carcinoma. This retrospective study investigates the impact of dose escalation on colostomy-free survival (CFS), overall survival (OS), locoregional control (LRC), progression-free survival (PFS), and acute and late toxicities in patients with squamous cell anal cancer. METHODS: Considered were the outcomes of 87 patients with anal cancer treated with radiation/RCT between May 2004 and January 2020 at our institution. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0). RESULTS: The 87 patients received treatment with a median boost of 63 Gy to the primary tumor. With a median follow-up of 32 months, the 3‑year CFS, OS, LRC, and PFS were 79.5%, 71.4%, 83.9%, and 78.5%, respectively. Tumor relapse occurred in 13 patients (14.9%). Dose escalation to > 63 Gy (maximum 66.6 Gy) to the primary tumor in 38/87 patients revealed a nonsignificant trend for improved 3‑year CFS (82.4% vs. 97%, P = 0.092), a significantly improved CFS for T2/T3 tumors (72.6% vs. 100%, P = 0.008), and a significantly improved 3‑year PFS for T1/T2 tumors (76.7% vs. 100%, P = 0.035). While acute toxicities did not differ, dose escalation > 63 Gy led to a higher rate of chronic skin toxicities (43.8% vs. 69%, P = 0.042). Treatment with intensity-modulated radiotherapy (IMRT) showed a significant improvement in 3‑year OS (75.4% vs. 53.8%, P = 0.048). In multivariate analysis, significant improvements for T1/T2 tumors (CFS, OS, LRC, PFS), G1/2 tumors (PFS), and IMRT (OS) were shown. The nonsignificant trend for CFS improvement with dose escalation > 63 Gy was also apparent in multivariate analysis (P = 0.067). CONCLUSION: Dose escalation > 63 Gy (maximum 66.6 Gy) may improve CFS and PFS for certain subgroups, with a concomitant increase in chronic skin toxicities. Modern IMRT seems to be associated with an improvement in OS. Springer Berlin Heidelberg 2023-03-02 2023 /pmc/articles/PMC10361861/ /pubmed/36862155 http://dx.doi.org/10.1007/s00066-023-02056-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Untiedt, Sebastian Rolf, Daniel Scobioala, Sergiu Wolters, Heidi Elsayad, Khaled Oertel, Michael Kittel, Christopher Pascher, Andreas Rijcken, Emile Ullerich, Hansjörg Glasbrenner, Bernhard Eich, Hans Theodor Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title | Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title_full | Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title_fullStr | Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title_full_unstemmed | Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title_short | Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
title_sort | impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361861/ https://www.ncbi.nlm.nih.gov/pubmed/36862155 http://dx.doi.org/10.1007/s00066-023-02056-y |
work_keys_str_mv | AT untiedtsebastian impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT rolfdaniel impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT scobioalasergiu impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT woltersheidi impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT elsayadkhaled impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT oertelmichael impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT kittelchristopher impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT pascherandreas impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT rijckenemile impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT ullerichhansjorg impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT glasbrennerbernhard impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma AT eichhanstheodor impactofdoseescalationoncolostomyfreesurvivalandtreatmentoutcomeinsquamouscellanalcarcinoma |